Background-New generation devices for transfemoral aortic valve replacement were optimized on valve positioning and reduction of residual aortic regurgitation. We compared 30-day, 12-month, and 24-month outcomes of the Boston Scientific Lotus valve (Lotus) and the balloon- 
T ransfemoral aortic valve replacement (TAVR) has been shown to be superior to surgical aortic valve replacement in patients at high and intermediate surgical risk. 1, 2 Residual aortic regurgitation (AR) 3 and procedural complications, for example, vascular access site and bleeding complications, are known to have an impact on long-term mortality. 4 New generation devices have been designed to optimize valve performance and reduce periprocedural complications. Innovations in valve design to reduce residual AR include an adaptable outer skirt for the third-generation balloon-expandable Edwards Sapien 3 (ES3) and an adaptive seal for the Boston Scientific Lotus valve (Lotus) filling the remaining gap between prosthesis and native annulus. Second, delivery catheter systems have been optimized, allowing lower profile to reduce vascular access site complications. Further innovations are aiming at a more precise valve control and positioning of the prosthesis in the native annulus. The Lotus is a mechanically deployed, completely repositionable, and retrievable TAVR device. First experiences with the device in 120 patients 5, 6 demonstrated a very low rate of moderate and severe AR and favorable clinical outcomes at 30 days and 1 year. 7 Long-term outcome of the Lotus compared with the balloon-expandable ES3 in a real-world TAVR population is missing. We compared 30-day, 12-month, and 24-month outcomes of the repositionable Lotus and the balloon-expandable ES3 in patients undergoing TAVR for severe symptomatic aortic stenosis.
Methods
Patients were prospectively enrolled in the Coronary and Structural Interventions-Ulm-Transcatheter Aortic Valve Replacement registry at the University of Ulm, Germany. Symptomatic severe aortic stenosis was confirmed by echocardiography and cardiac catheterization with an aortic valve area ≤1 cm 2 or an indexed aortic valve area ≤0.6 cm 2 / m 2 . Patients underwent diagnostic evaluation with routine laboratory testing, medical history with current medication, Society of Thoracic Surgeons score, logistic EuroScore, New York Heart Association classification, ECG, echocardiography, heart catheterization, and a multislice computed tomography. Multislice computed tomography was used for sizing and evaluated for aortic annulus, left ventricular outflow tract, distance from annulus to coronary ostia, and area at ostia with a dedicated software (3mensio software; Pie medical Imaging, Maastricht, the Netherlands) according to present guidelines. 6, 8, 9 Device selection was done according to the flowchart displayed in Figure 1 . Calcification of aortic cusps was assessed according to Rosenhek et al. 10 Decision about suitability for TAVR was assessed by the heart team. Intermediate to high surgical risk was defined based on Society of Thoracic Surgeons score for mortality and relevant comorbidities, including contraindications for surgical valve replacement as chest radiation or porcelain aorta. The study complies with the Declaration of Helsinki and was approved by the ethics committee of the University of Ulm, and written informed consent was obtained from all patients. Procedures were performed via transfemoral access using local anesthesia under conscious sedation as described elsewhere. 6, 9, 11 In all patients, the Perclose Proglide vascular closure device was used. There was no surgical cut-down. Anticoagulation was measured by activated clotting time with repetitive administration of unfractionated heparin. Implantation was done under fluoroscopic guidance in the orthogonal view of the annulus. Rapid pacing was used during implantation of the balloon-expandable ES3 valve. No rapid pacing was used with the Boston Lotus valve featured with an early valve operation to ensure hemodynamic stability during implantation procedure.
Clinical outcomes were assessed according to the Valve Academic Research Consortium-2 criteria. 12 Standardized aortography was done to analyze postprocedural AR. 6, 9 Pressure gradients and AR were assessed by transthoracic echocardiography after the procedure. AR was graded as described elsewhere. 6, 9, 13 Follow-up was done at 12 and 24 months, assessing the early safety end point according to Valve Academic Research Consortium-2 criteria and the combined end point of all-cause mortality or disabling stroke at 12 and 24 months.
The Lotus
The Lotus (Boston Scientific Corporation, Marlborough, MA) was available since January 2014 in sizes of 23 and 27 mm, with the addition of a 25 mm device from May 2015. The 23 mm valve is inserted via an 18F, and the 25 and 27 mm devices via a 20F sheath with a hydrophilic surface. The Lotus valve has a nitinol frame with an Adaptive Seal technology to reduce paravalvular AR. The Lotus valve system is fully retrievable and bidirectional repositionable. No rapid pacing was used with the Boston Lotus valve, which begins to function early during the implantation procedure, to ensure hemodynamic stability. Even after having been locked in its final position, the valve can still be completely retrieved. During deployment, the valve shortens to a final height of 19 mm.
The ES3 Valve
The third-generation balloon-expandable ES3 valve was available since February 2014 in 23, 26, and 29 mm sizes. The 23 and 26 mm devices are delivered via a 14F and the 29 mm via a 16F expandable sheath. The delivery system allows a fine positioning of the valve before balloon inflation. An outer skirt, covering about one third of the distal part of the frame, made of polyethylene terephthalate reduces the occurrence of paravalvular AR. Valve positioning was done with the bottom of the center marker at the base of cusps.
Statistical Analysis
Categorical parameters are presented as counts and percentages and were compared by Pearson χ 2 test. Continuous variables are presented as mean±SD and were compared with t test. Primary outcome measure was a composite of all-cause mortality or disabling stroke. To account for differences between the 2 nonrandomized groups, we performed propensity score analysis based on an optimal matching attempt (SAS 9.4; SAS Institute GmbH, Heidelberg, Germany). Matching was done for Society of Thoracic Surgeons score, age, atrial fibrillation, left ventricular ejection fraction, previous permanent pacemaker, annulus diameter, aortic cusp calcification, availability of 12-month follow-up, and left ventricular outflow tract calcification. Survival curves are based on available follow-up and performed with use of Kaplan-Meier estimates and were compared with logrank testing. A P value <0.05 was considered to be statistically significant. Statistical analysis was performed using Statistica release 10 (StatSoft, Tulsa, OK).
Results

Patient Population and Baseline Parameters
Between 2014 and 2016, consecutive patients treated with the Lotus (n=202) or the ES3 (n=335) were enrolled. Patients presented with multiple comorbidities at baseline (Table I in the Data Supplement). Society of Thoracic Surgeons score for mortality was high in both groups with no significant difference. Baseline characteristics between groups were similar except for significant lower rates of preexistent permanent pacemaker before TAVR in the ES3 population (Table I in the Data Supplement). Cardiac catheterization and transthoracic echocardiography demonstrated severe aortic stenosis (Table  II in the Data Supplement). Analyses of multislice computed tomography for the 2 device groups are detailed in Table II in the Data Supplement. Diameters of left ventricular outflow tract and aortic annulus were significantly larger in the ES3 group based on the availability of a 29 mm device. Calcifications of aortic cusps and left ventricular outflow tract were similar for both groups. In the propensity score-matched population, including 404 patients, baseline data did not differ between groups (Tables 1 and 2 ).
Procedural Results and Outcome
All patients were successfully treated with a single valve. With the mechanically deployed Lotus valve, balloon predilation
WHAT IS KNOWN
• Transfemoral aortic valve replacement with new generation devices has been shown to be associated with a lower risk of moderate or severe aortic regurgitation compared with first-generation devices.
• Implantation techniques differ substantially between new generation devices (eg, between balloonexpandable valve, mechanically expandable, and self-expanding valves), which can be repositioned or even retrieved, potentially offering an improved control during the procedure.
WHAT THE STUDY ADDS
• This study compares a relatively large number of patients who received a balloon-expandable ES3 valve or a repositionable Lotus, with 2-year follow-up.
• Postprocedural results, echocardiographic data, and clinical follow-up ≤2 years were comparable between both valve types in a propensity scorematched population, except for a significantly higher incidence of permanent pacemaker implantation with the mechanically implanted Lotus valve.
was significantly less frequent (87.6% versus 93.5%; P=0.04; Table 3 ). Mean valve size was significantly larger in the ES3 group with 26.0±2.4 versus 25.4±1.5 mm (P<0.01; Table III in the Data Supplement). In the propensity-matched population, there was no significant difference in mean valve size (ES3, 25.6±2.3 mm versus Lotus, 25.4±1.5 mm; P=0.23). The most frequently used valve sizes were the 26 mm ES3 and the 25 mm Lotus. There was no moderate or severe AR after TAVR with both devices. Postdilation was necessary only in 1 patient (0.3%) after implantation of the ES3 device and was not necessary after implantation of the Boston Lotus valve. Rate of mild AR was lower with the repositionable and retrievable Lotus valve both by angiography and echocardiography (Table 3 ). Resheathing to optimize valve positioning and minimize AR with the mechanically deployed Lotus system was used in 47% of cases (n=95). There was no associated disabling stroke in patients with resheathing of the Lotus valve. In 2 patients with resheathing, a transitory ischemic attack occurred 24 hours and 8 days postprocedure. Contrast amount was low, although significantly higher at a difference of 5 mL with use of the repositionable device (P=0.03). There was 1 coronary obstruction in a patient treated with the Lotus because of embolized calcium, which needed hemodynamic support by extracorporal life support for stenting of left main occlusion. No annular rupture was noted with either of the devices (Table 3) . Mean aortic gradient assessed by TTE was similar between devices. Rate of major vascular complications was similar for the 2 devices (ES3, 2.9% versus Lotus, 3.5%; P=0.78). Rate of mild AR was lower with the Lotus compared with the ES3 valve (Table 3) .
Early safety end point at 30 days was low in both groups (Table IV in Follow-up for 12 months was available in 287 (ES3, n=185; Lotus, n=102) patients (100% of eligible patients; Table V in the Data Supplement). After propensity matching, 204 patients (ES3, n=102; Lotus, n=102) were available for 12-month follow-up. In the propensity-matched population, total follow-up time was 140.7 patient years in patients treated with the ES3 valve compared with 133.5 patient years in the Boston Lotus group (P=0.30), corresponding to a mean follow-up time of 1.39±0.6 years in the ES3 and 1.31±0.5 years in the Boston Lotus group. The composite end point of all-cause mortality or disabling stroke after 12-month follow-up was statistically not different with 15.5% for the Lotus valve and 18.6% for the Sapien 3 (P=0.69; Table 5 ). In the Boston Scientific Lotus group at 12 months of follow-up, there were 2 patients experiencing stroke, who died during follow-up. Disabling stroke-free survival was similar between groups as shown in Figure 2 . There was 1 case of aortic valve endocarditis in each group. There was no repeat procedure for valve-related dysfunction with either of the devices. Within 12 months of follow-up, there was no significant difference in valve performance. Mean aortic gradient was 12.8±5.1 mm Hg for the ES3 versus 11.6±3.9 mm Hg for the Boston Lotus valve (P=0.26). Of the 537 patients included, 177 were eligible for 24-month follow-up (Table VI in the Data Supplement). In 168 patients (ES3, n=121; Lotus, n=47), follow-up was available (95% follow-up rate). In the propensity-matched population, 24-month follow-up was available in 116 patients (ES3, n=69; Lotus, n=47). Within 24 months, the outcome was similar between the 2 TAVR devices, without any significant difference in outcome (Table 6 ). In the propensity-matched population, rate of disabling stroke was 5.8% with the Lotus valve versus 3.3% with the ES3 (P=0.38). Within 24 months of follow-up, a total of 3 patients in the Lotus valve group experienced stroke and 
Discussion
The repositionable Lotus and the balloon-expandable ES3 valve showed similar 30-day, 12-month, and 24-month outcomes in patients undergoing transfemoral aortic valve implantation. Rate of none or trace postprocedural AR was lower, although need for pacemaker implantation was significantly higher with the Lotus compared with the ES3 valve.
Both valve types include a dedicated design to reduce the risk of relevant residual paravalvular AR. The balloonexpandable Edwards Sapien S3 valve has an outer skirt at the distal part of the frame, aimed to fill the remaining gap between the prosthesis and the native annulus. The Lotus can be repositioned to optimize implantation and is provided with an Adaptive Seal technology to reduce paravalvular AR. We are able to demonstrate the absence of moderate and severe AR with both new generation devices in 537 patients. Moderate and severe AR had a significant negative clinical impact with last generation devices 3 and has been reported in ≤20%. 1, 4, 14 In a first experience, including 150 patients with the ES3 valve, moderate or severe AR was found in 3.8%. 15 In a multicenter study evaluating 12-month outcome with the ES3 valve in 583 patients, moderate AR was present in 2.7% of patients and associated with an increase in 12-month mortality. 16 In the REPRISE II study (Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System), there was no moderate or severe AR in 120 patients treated with the Lotus. 7 Multicenter registry data from the United Kingdom, including 228 patients reported mild AR in 22.4% of cases, as well as 0.4% of moderate and severe AR with postdilation performed in 1.3% of patients. 17 The Nordic Lotus registry with 154 patients reported 1 case of moderate AR, requiring postdilation. 18 In our population, the rate of residual AR after valve implantation was lower after implantation of the Lotus valve, using the repositioning feature in 47% of cases. There was only 1 case of postdilation with an ES3 valve for moderate AR resulting in mild AR. Postdilation after ES3 valve has been reported in ≤34% 6, 14, 19, 20 and has been linked to an increase in thromboembolic events. 3 Within 30 days, rate of disabling stroke did not differ with 1.5% for the Boston Lotus valve and 0.9% for the ES3 valve (P=0.65). Of note, occurrence of stroke was not related to repositioning of the Lotus valve. In the REPRISE II study, rate of disabling stroke with the Lotus was 1.7% 5 and rate of disabling stroke was comparable in the prospective postmarket multicenter RESPOND registry (Re-Positionable Lotus Valve System -Post Market Evaluation of Real World Clinical Outcomes; presented at EuroPCR 2016 Euro16A-OP021) with 2.2% at 30 days. The UK registry 17 reported 3.2% rate of all stroke within 30 days, whereas it was 3.9% until discharge in the Nordic Lotus-TAVR registry. 18 In the PARTNER-2 trial 1 (Placement of Aortic Transcatheter Valve), using the Edwards Sapien XT in intermediate-risk patients rate of disabling stroke at 30 days was 2.2% for the transfemoral route, thus comparable to our population. TAVR with the ES3 in intermediate-risk patients was associated with a stroke rate of 2.7%, 1 similar to surgical valve replacement. Dual-filter-based cerebral emboli protection systems or use of a deflector is an approach to further reduce periprocedural ischemic events 21, 22 with capturing rates ≤99% with filter systems.
Early safety end point at 30 days was similar for both valve types and with comparable outcomes for all-cause mortality and disabling stroke. For the Lotus valve, the Nordic Lotus-TAVR registry, including 154 patients, reported a similar early safety rate of 7.8% at 30 days. 18 Major vascular complications for TAVR with the Edwards Sapien XT in PARTNER-2 occurred in 7.9%. The third-generation ES3 was optimized for lower profile to reduce access site complications. However, with the expandable sheaths technology, outer diameters are increasing ≤8.6 mm when the valve is advanced. Hence outer diameter of the vascular sheath is expanded to a similar diameter when using the ES3 or the Boston Lotus valve explaining the similar rates in vascular complications and bleedings. In our population, rate of major vascular complication was low for both devices with 3.5% for the ES3 and 2.9% for the Lotus (P=0.78). For the ES3, rate of major vascular complications are reported between 4.2% 15 and 6.1%. 1 For the Lotus valve, results were 2.5% in the REPRISE II study, 5 2.6% in the Nordic Lotus-TAVR registry, 18 and 7.0% in the UK Lotus registry. 17 Comparing the need for pacemaker implantation, rate was significantly higher with implantation of the mechanically deployed Lotus compared with the balloon-expandable ES3 (36.1% versus 15.4%, P<0.01). For the ES3, Webb et al 15 reported comparable rates of 12.5% new pacemaker implantation at 30 days. In the large Sapien 3 observational study 1 in 1077 patients, need for new pacemaker implantation was 10.2% at 30 days. After Lotus valve implantation, rate of permanent pacemaker implantation was 28.6% in REPRISE II, 5, 7 27.9% in the Nordic Lotus-TAVR registry (18) , and 31.8% in the UK Lotus registry. 17 The impact of permanent pacemaker implantation on outcome is controversial. [23] [24] [25] However, as TAVR approaches to intermediate-risk and younger patients, rate of pacemaker implantation may represent a limitation for the mechanically deployed device. Second, in patients with an impaired left ventricular function, pacemaker implantation might be associated with a further decrease in left ventricular function.
In PARTNER-1 2 comparing the Edwards valve with surgical valve replacement in high-risk patients, the combined end point of all-cause mortality or disabling stroke was 33.0% in TAVR patients and 50.3% in surgical treated patients (P=0.001). In PARTNER-2 1 comparing the Edwards Sapien XT valve with surgical valve replacement, the combined end point of all-cause mortality and disabling stroke was 14.5% in TAVR patients and 16.4% in surgical treated patients at 1 year (P=0.24). The ES3 valve showed 17.2% rate of all-cause mortality and stroke in 583 high-risk and inoperable patients 16 and 8.4% in 1077 intermediate-risk patients. 1 Comparing longterm results over 12 and 24 months of follow-up, there was no significant difference in rate of all-cause mortality or stroke between patients treated with the Lotus and patients treated with the ES3 valve.
Limitations
This is no randomized controlled trial, although a large single-center experience comparing 30-day, 12-month, and 24-month outcomes with the repositionable Lotus valve and the balloon-expandable ES3 in patients undergoing TAVR for severe aortic stenosis, including the standardized Valve Academic Research Consortium-2 criteria. The study is limited by the differences at baseline between both arms because there All percentages are Kaplan-Meier estimates at the specific time point. P values are for the point-in-time comparisons. Outcome With a Repositionable Versus Balloon-Expandable TAVR Device was no randomization for device type resulting in a selection bias, which were addressed with propensity matching.
Conclusions
TAVR with the ES3 and the Lotus was associated with similar 30-day, 12-month, and 24-month clinical outcome. Rate of mild AR was lower with the repositionable and retrievable Lotus valve compared with the ES3. Need for permanent pacemaker implantation was significantly higher with the repositionable Lotus device.
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